司爾特(002538.SZ)半年度淨利潤預增40%-90%
格隆匯6月23日丨司爾特(002538.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤約1.87億元–約2.54億元,同比增長40%-90%。主要原因是:
(1)受益於國內國際雙循環戰略的實施、國際需求量的增加和糧食產品價格的上漲,化肥行業持續回暖,2021年上半年的產品價格增長,尤其是硫鐵礦制硫酸的整體效益及磷酸一銨市場平均價格較上年同期增長較大;
(2)公司產品出口增多;
(3)報吿期內公司收購了貴州路發實業有限公司,公司擁有的優質磷礦資源和公司已擁有的硫鐵礦資源已產生了效益,更得益於一體化產業鏈優勢,在市場上原材料成本大幅上升的時候,公司能較好的控制成本,取得效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.